Biotech Values

[ciotera]

drugs developed in-house by Big Pharma are 20% more likely to obtain regulatory approval

I don't know how the 20% was computed, but if the sample of drugs considered included brand extensions and "related" molecules then it wouldn't really be surprising - it's much easier to get approval for a modified version of an already approved product vs. in-licensed candidates are almost always truly innovative and as such more risky.